Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00592267 |
|
Recruitment Status :
Recruiting
First Posted : January 14, 2008
Last Update Posted : March 8, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Pediatric Bipolar Disorder |
To address the urgent therapeutic needs of children and adolescents ages 4-17 with pediatric bipolar disorder, we have designed a series of clinical trials aimed at evaluating critical components of the treatment needs of this under-served and under-researched population. This approach will allow us to provide a full complement of clinical trials that will meet the most pressing needs of the bipolar children and adolescents and their families who are currently awaiting treatment.
Although these protocols have received prior IRB approval, potential participants present with a widely varied set of complaints not always discernable in a telephone screening interview. This state of affairs makes it very difficult to ask subjects to sign a specific clinical protocol without obtaining additional clinical information. Because of this we are proposing potential subjects to consent to undergo an in-depth clinical assessment that will allow subjects to be screened by a clinician for eligibility to a diverse clinical trials program available to them.
| Study Type : | Observational |
| Estimated Enrollment : | 1000 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Prospective |
| Official Title: | A Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder |
| Study Start Date : | September 2001 |
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | December 2020 |
| Group/Cohort |
|---|
| 1 |
- Screening Protocol [ Time Frame: Study Enrollment ]This protocol is a prescreening for other research studies.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 4 Years to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Males and females age 4 to 17 inclusive with a suspected diagnosis of bipolar disorder.
- Subject and parent/ legal guardian must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.
- Subjects and their parent/ legal representative must be considered reliable.
- Each subject and his/her parent or authorized legal representative must understand the nature of the study. The subject's parent or authorized legal representative must sign an informed consent document and the subject must sign an informed assent document.
- One parent/ legal guardian must be able to accompany the subject to the clinic at each visit.
Exclusion Criteria:
- Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild.
- Serious, unstable illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease
- Mental retardation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00592267
| Contact: Rebecca Wolenski | 617-643-6617 | rwolenski@partners.org | |
| Contact: Alexa Pulli, BS | 617-726-4651 | apulli@mgh.harvard.edu |
| United States, Massachusetts | |
| Masschusetts General Hospital | Recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: | Joseph Biederman, MD | Massachusetts General Hospital |
Additional Information:
| Responsible Party: | Joseph Biederman, MD, Chief, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT00592267 History of Changes |
| Other Study ID Numbers: |
2001-P-001247 |
| First Posted: | January 14, 2008 Key Record Dates |
| Last Update Posted: | March 8, 2018 |
| Last Verified: | March 2018 |
Keywords provided by Joseph Biederman, MD, Massachusetts General Hospital:
|
pediatric bipolar disorder |
Additional relevant MeSH terms:
|
Disease Bipolar Disorder Pathologic Processes Bipolar and Related Disorders Mental Disorders |